CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
1. CorMedix completed acquisition of Melinta Therapeutics, expanding its product portfolio. 2. Expected combined revenue for 2025 is $325 to $350 million. 3. Acquisition projected to contribute double-digit EPS growth by 2026. 4. DefenCath® and REZZAYO™ expected to generate significant future revenues. 5. Operational synergies anticipated in the range of $35 to $45 million.